A Phase I/II Study of the Combination of BKM120 and Bevacizumab, Glioblastoma Multiforme
What is the purpose of this trial?
Primary Objective Phase I
To establish the optimal dose of BKM120 that can be administered in combination with a standard dose of bevacizumab.
Primary Objective Phase II
To evaluate the efficacy of the BKM120/bevacizumab combination in patients with relapsed/refractory GBM. For evaluation of efficacy, patients previously treated with bevacizumab will be considered separately from those with no previous bevacizumab treatment.
- 18 Years and older
- Sarah Cannon Research Institute Oncology Research Consortium
- Last Updated:
- Study HIC#: